Metabolic effects of androgen deprivation therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review or meta-analysis methodology
PubMed 25598932 · doi:10.4111/kju.2015.56.1.12
What was done
The authors searched KoreaMed and PubMed to review medical literature on the metabolic effects of androgen deprivation therapy (ADT) for prostate cancer, specifically evaluating body habitus, insulin resistance, lipid profiles, diabetes, metabolic syndrome, and cardiovascular morbidity and mortality.
What was found
The abstract reports no numerical data. Qualitatively, ADT increases fat mass (predominantly subcutaneous) and decreases lean body mass. ADT increases total cholesterol, triglycerides, high-density lipoprotein, insulin resistance, and the risk of diabetes and cardiovascular events. Insufficient evidence was reported regarding an association with cardiovascular mortality.
Why it matters
It characterizes the specific metabolic profile associated with ADT, emphasizing the need for clinicians to monitor and manage diabetes and cardiovascular risks in treated prostate cancer patients.
Limits
This is a narrative review that reports no search dates, inclusion criteria, study quality assessments, or sample sizes. No quantitative effect sizes, odds ratios, or confidence intervals are provided.
Cited by
- supports Androgen deprivation therapy in prostate cancer patients typically causes increased fat mass, loss of muscle mass, elevated cardiovascular disease risk, and insulin resistance or diabetes.